Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M K, Bowling"'
Autor:
Eric K. Rowinsky, David S. Ettinger, T L Chen, S E Sartorius, Scott H. Kaufmann, Ross C. Donehower, David M. Peereboom, M K Bowling, Louise B. Grochow, Arlene A. Forastiere, Sharyn D. Baker
Publikováno v:
Journal of Clinical Oncology. 14:3074-3084
PURPOSE A phase I and pharmacologic study was performed to evaluate the feasibility of administering the topoisomerase I (topo I) inhibitor topotecan (TPT) in combination with cisplatin (CDDP) in minimally pretreated adults with solid tumors. The stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::354a814cf3c180c68afae7f4a4068815
https://doi.org/10.1200/jco.1996.14.12.3074
https://doi.org/10.1200/jco.1996.14.12.3074
Autor:
M K Bowling, Eric K. Rowinsky, T L Chen, Ross C. Donehower, William P. McGuire, William Slichenmyer
Publikováno v:
Cancer Chemotherapy and Pharmacology. 36:227-232
Histamine-2 receptor antagonists (H2RAs) are principal components of the premedication regimen used to prevent major hypersensitivity reactions in patients receiving paclitaxel. Several different H2RAs, including cimetidine, ranitidine and famotidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f862ff7f5e2ce541a80a0f743b5e3a22
https://doi.org/10.1007/bf00685851
https://doi.org/10.1007/bf00685851
Autor:
M A, Carducci, J, Gilbert, M K, Bowling, D, Noe, M A, Eisenberger, V, Sinibaldi, Y, Zabelina, T L, Chen, L B, Grochow, R C, Donehower
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(10)
Sodium phenylbutyrate (PB) demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. We conducted a Phase I and pharmacokinetic study of PB by continuous infusion to characterize the maximum tolerated dose, to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc0d8905d3a114b2c3a06e6d1700fa30
https://pubmed.ncbi.nlm.nih.gov/11595694
https://pubmed.ncbi.nlm.nih.gov/11595694
Autor:
J, Gilbert, S D, Baker, M K, Bowling, L, Grochow, W D, Figg, Y, Zabelina, R C, Donehower, M A, Carducci
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
Phenylbutyrate (PB) is an aromatic fatty acid with multiple mechanisms of action including histone deacetylase inhibition. Preclinically, PB demonstrates both cytotoxic and differentiating effects at a concentration of 0.5 mM. We conducted a Phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f73324d963d70cf97fa06d247ebf6987
https://pubmed.ncbi.nlm.nih.gov/11489804
https://pubmed.ncbi.nlm.nih.gov/11489804
Autor:
E K, Rowinsky, G S, Long, D A, Noe, L B, Grochow, M K, Bowling, S E, Sartorius, R C, Donehower
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(3)
CI-980 (NSC 613862) is one of a novel class of 1,2-dihydropyrido[3, 4-b]pyrazines that inhibits tubulin polymerization, presumably by binding to the colchicine binding site of tubulin. In a Phase I and pharmacological study, 16 patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc59732da100fba35cf7d8fe47fb77f2
https://pubmed.ncbi.nlm.nih.gov/9815698
https://pubmed.ncbi.nlm.nih.gov/9815698
Autor:
Louise B. Grochow, Eric K. Rowinsky, David M. Peereboom, Scott H. Kaufmann, S E Sartorius, M K Bowling, Ross C. Donehower
Publikováno v:
Europe PubMed Central
PURPOSE To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF schedulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edee329d4fe50d7d61ce71e605822148
https://pubmed.ncbi.nlm.nih.gov/8648378
https://pubmed.ncbi.nlm.nih.gov/8648378
Publikováno v:
Seminars in oncology. 22(4 Suppl 9)
Preliminary results of a phase I study of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), given by 3-hour infusion, followed by carboplatin in chemotherapy-naive patients with stage IV non-small cell lung cancer indicate that both ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::82e7a0e5bcc246c276dda7ec8b015cb3
https://pubmed.ncbi.nlm.nih.gov/7644928
https://pubmed.ncbi.nlm.nih.gov/7644928
Publikováno v:
Cancer chemotherapy and pharmacology. 36(3)
Histamine-2 receptor antagonists (H2RAs) are principal components of the premedication regimen used to prevent major hypersensitivity reactions in patients receiving paclitaxel. Several different H2RAs, including cimetidine, ranitidine and famotidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d02a5356e8394e3d90608d673d3c0e80
https://pubmed.ncbi.nlm.nih.gov/7781143
https://pubmed.ncbi.nlm.nih.gov/7781143
Autor:
M K Bowling, T L Chen, Ross C. Donehower, Scott H. Kaufmann, Dennis A. Noe, Louise B. Grochow, Eric K. Rowinsky, S E Sartorious, B G Lubejko
Publikováno v:
Europe PubMed Central
PURPOSE To determine the maximum-tolerated doses (MTDs), principal toxicities, and pharmacologic behavior of pyrazoloacridine (PZA), a novel DNA intercalator with a unique mechanism of action, on single- and multiple-dosing schedules. PATIENTS AND ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afae460f1f497468aa1ef6b7d5d32e2f
http://europepmc.org/abstract/med/7636538
http://europepmc.org/abstract/med/7636538
